The Effects of Increased Glucose Level and Glycolysis on SARS CoV-2 Infection.
Antiviral research
COVID-19 treatment
SARS-CoV-2
diabetes
glucose level
glycolysis inhibition
Journal
Mini reviews in medicinal chemistry
ISSN: 1875-5607
Titre abrégé: Mini Rev Med Chem
Pays: Netherlands
ID NLM: 101094212
Informations de publication
Date de publication:
2022
2022
Historique:
received:
19
11
2021
revised:
12
12
2021
accepted:
20
12
2021
pubmed:
22
3
2022
medline:
24
9
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
COVID-19 has entered our lives as an infection with high mortality rates. Although the vaccination process has provided benefits, the death toll remains frightening worldwide. Therefore, drugs and combined therapies that can be used against COVID-19 infection are still being investigated. Most of these antiviral medications are investigational drug candidates that are still in clinical trials. In this context, holistic and different approaches for the treatment of COVID-19, including prophylactic use of natural medicines, are under investigation and may offer potential treatment options due to the fact that this is still an unmet medical need of the world. Thus, inhibiting the increased glycolysis in COVID-19 infection with glycolysis inhibitors may be beneficial for patient survival. This short review highlights the potential benefits of glycolysis inhibition as well as controlling the elevated glucose levels in patients with COVID-19.
Identifiants
pubmed: 35306995
pii: MRMC-EPUB-121689
doi: 10.2174/1389557522666220318115350
doi:
Substances chimiques
Antiviral Agents
0
Drugs, Investigational
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2344-2349Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.